35144-64-0|Aldophosphamide|Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-, 3-oxopropyl ester|-范德生物科技公司

Aldophosphamide

NMR下载 COA and HPLC MSDS下载
names：
Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-, 3-oxopropyl ester
CAS号：
35144-64-0
MDL Number：
MF(分子式)： C7H15Cl2N2O3P MW(分子量)： 277.0818
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Aldophosphamide
英文别名	Aldophosphamide
CAS号	35144-64-0
Inchi	InChI=1S/C7H15Cl2N2O3P/c8-2-4-11(5-3-9)15(10,13)14-7-1-6-12/h6H,1-5,7H2,(H2,10,13)
InchiKey	QMGUSPDJTPDFSF-UHFFFAOYSA-N
分子式 Formula	C7H15Cl2N2O3P
分子量 Molecular Weight	277.0818
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Aldophosphamide(CAS:35144-64-0):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Aldophosphamide has apoptotic antitumor activity.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Voelcker G. Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activity. Anticancer Drugs. 2018 Jan;29(1):75-79. doi: 10.1097/CAD.0000000000000569. PubMed PMID: 29219879.

[2]Voelcker G. Influence of the alkylating function of aldoifosfamide on the antitumor activity. Anticancer Drugs. 2017 Oct 3. doi: 10.1097/CAD.0000000000000569. [Epub ahead of print] PubMed PMID: 28984684.

[3] Wang J, Wang YJ, Chen ZS, Kwon CH. Synthesis and evaluation of sulfonylethyl-containing phosphotriesters of 3'-azido-3'-deoxythymidine as anticancer prodrugs. Bioorg Med Chem. 2014 Nov 1;22(21):5747-56. doi: 10.1016/j.bmc.2014.09.046. Epub 2014 Sep 28. PubMed PMID: 25440502.

[4] Parajuli B, Georgiadis TM, Fishel ML, Hurley TD. Development of selective inhibitors for human aldehyde dehydrogenase 3A1 (ALDH3A1) for the enhancement of cyclophosphamide cytotoxicity. Chembiochem. 2014 Mar 21;15(5):701-12. PubMed PMID: 24677340; PubMed Central PMCID: PMC4043872.

[5] Parajuli B, Fishel ML, Hurley TD. Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells. J Med Chem. 2014 Jan 23;57(2):449-61. doi: 10.1021/jm401508p. Epub 2014 Jan 10. PubMed PMID: 24387105; PubMed Central PMCID: PMC3988914.

6: Bacolod MD, Lin SM, Johnson SP, Bullock NS, Colvin M, Bigner DD, Friedman HS. The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. Curr Cancer Drug Targets. 2008 May;8(3):172-9. PubMed PMID: 18473730; PubMed Central PMCID: PMC3633091.7: Liang J, Huang M, Duan W, Yu XQ, Zhou S. Design of new oxazaphosphorine anticancer drugs. Curr Pharm Des. 2007;13(9):963-78. Review. PubMed PMID: 17430192.8: Patzer L, Hernando N, Ziegler U, Beck-Schimmer B, Biber J, Murer H. Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells. Kidney Int. 2006 Nov;70(10):1725-34. Epub 2006 Sep 27. PubMed PMID: 17003823.9: Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, Duan W, Zhu YZ. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev. 2005;37(4):611-703. Review. PubMed PMID: 16393888.10: Jain M, Fan J, Baturay NZ, Kwon CH. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines. J Med Chem. 2004 Jul 15;47(15):3843-52. PubMed PMID: 15239662.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开